IDXXIDXXHealthcare · Diagnostics & Research

IDXX Stock Forecast: IDEXX Laboratories, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$676
−1.91% on the day

The 14 Wall Street analysts covering IDEXX Laboratories, Inc. hold a median 12-month price target of $718 — +6.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 91 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$53.3B
Ticker Nerd rank
91/ 100
Median analyst target
$718
Analysts covering
14
Revenue$1.2B+9.7% y/y
Operating income$425.6M
Net income$338.4M
Free cash flow$320.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
+21.2%
YTD
−0.0%
1Y
−1.9%
From 52W high
−11.8%
From 52W low
+34.0%
$505
$767
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores IDEXX Laboratories, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
91/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Issuance
96
Volatility
96
Value
82
Revisions
77
Growth
66
Momentum
64
Accruals
41

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (41): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IDXX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IDXX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800Jan 26Apr 26Jul 26Oct 26IDXXHigh $810Median $718Low $470

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
9
Buy
4
Hold
1
Sell
$470
Low
$718
Median
$810
High

The green dot is the last close — the median target sits +6.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
3 Nov 2026Morgan StanleyMaintainsOverweight$805 → $810
3 Nov 2026UBSMaintainsNeutral$627 → $700
27 Oct 2026UBSMaintainsNeutral$670 → $627
16 Oct 2026JP MorganMaintainsOverweight$775 → $750
12 Oct 2026KeybancInitiatesSector Weight—
11 Aug 2026BarclaysMaintainsOverweight$800 → $710
5 Aug 2026CitigroupMaintainsNeutral$650 → $670
5 Aug 2026UBSMaintainsNeutral$620 → $670
27 July 2026UBSMaintainsNeutral$640 → $620
28 Apr 2026UBSMaintainsNeutral$730 → $640
15 Apr 2026CitigroupInitiatesNeutral—
31 Mar 2026StifelMaintainsBuy—
9 Feb 2026Piper SandlerMaintainsNeutral—
5 Feb 2026BarclaysMaintainsOverweight—
3 Feb 2026BTIGMaintainsBuy—
3 Feb 2026UBSMaintainsNeutral—
9 Dec 2025BarclaysInitiatesOverweight—
4 Nov 2025BTIGMaintainsBuy—
4 Nov 2025JP MorganMaintainsOverweight—
4 Nov 2025Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IDXX.

Market Radar

This page is one stock. Monday covers all of them.

IDXX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

IDXX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, IDEXX Laboratories, Inc. returned −1.9% against +6.9% for the S&P 500, dividends included.

IDXX vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26IDXXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IDXX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+1.3%
Analysts raising
6
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
45.6×

Cheaper than 18% of US stocks

Price / sales
11.4×

Cheaper than 11% of US stocks

Price / book
28.5×

Cheaper than 2% of US stocks

EV / EBITDA
32.3×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
9.9%

Higher than 53% of US stocks

Earnings growth (YoY)
15.5%

Higher than 55% of US stocks

Gross margin
64.0%

Higher than 77% of US stocks

Operating margin
32.5%

Higher than 89% of US stocks

Net margin
25.4%

Higher than 85% of US stocks

Returns & dividend
Return on equity
68.9%

Higher than 95% of US stocks

Return on assets
26.7%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IDEXX Laboratories, Inc. has a market value of $53.3B and an enterprise value of $54.1B.

  • Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 9.7% year on year.

  • Net income over the same four quarters: $1.1B, a 25.0% net margin.

  • Diluted earnings per share, trailing twelve months: $14.22.

  • Free cash flow in the twelve months to 30 June 2026: $1.2B.

  • IDEXX Laboratories, Inc. spent $1.2B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 78.9M.

  • Trailing P/E: 45.6×; forward P/E: 40.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • IDEXX Laboratories, Inc. employs 11,000 people — $414K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

IDXX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
IDXXIDEXX Laboratories, Inc.$53.3B91
AAgilent Technologies, Inc.$48.3B85
WATWaters Corp.$43.2B52
IQVIQVIA Holdings, Inc.$40.5B83
NTRANatera, Inc.$39.6B70
MTDMettler-Toledo International, Inc.$34.1B96
LHLabcorp Holdings, Inc.$30.4B88

Take a look at IDXX’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own IDEXX Laboratories, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IDXX

What is the IDXX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering IDEXX Laboratories, Inc. have a median 12-month price target of $718, with estimates ranging from $470 to $810. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IDXX stock a buy right now?

Of the 14 analysts covering IDEXX Laboratories, Inc., 9 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks IDEXX Laboratories, Inc. 91 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IDXX?

As at 21 Nov 2026, IDEXX Laboratories, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will IDXX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +6.1% from the last close, and Ticker Nerd's factor model ranks IDEXX Laboratories, Inc. 91 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IDXX stock forecast for 2030?

No analyst covering IDEXX Laboratories, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IDXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $470 to $810 over the next 12 months.

How has IDXX stock performed over the past year?

IDEXX Laboratories, Inc. returned -1.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IDEXX Laboratories, Inc. do?

IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals.

Company

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a global diagnostics and software company focused on animal health, water quality, and agricultural testing. IDEXX Laboratories, Inc. develops and supplies in-clinic veterinary diagnostic instruments, consumable test kits, reference laboratory services, and practice management software that help veterinarians diagnose and monitor companion animals. The company also provides testing solutions for livestock, poultry, and dairy producers, along with water microbiology products used to assess drinking water safety and quality. Its product portfolio is built around recurring consumables, laboratory workflows, and integrated software tools that support everyday clinical and operational decisions. IDEXX Laboratories, Inc. serves veterinary practices, animal health professionals, utilities, and food-production customers across global markets, making it an important provider of diagnostic infrastructure in the broader healthcare and environmental testing ecosystem.

CEO Mr. Michael G. Erickson Ph.D. · 11,000 employees · United States · https://www.idexx.com